Skip to main contentSkip to navigationSkip to search
Curasight
  DKK  % |
Curasight

Directed issues registered at the Danish Business Authority

July 1, 2024

Regulatory

Copenhagen, Denmark, 01 July 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) today announces that the directed issues decided by the Board of Directors and announced on the 14[th] of June 2024 are now registered at the Danish Business Authority. The directed issues increase the Company's number of shares from 19,893,891 to a total of 20,682,427 shares. The Company's share capital will increase from DKK 994,694.55 to a total of DKK 1,034,121.35. The new shares are expected to be in the subscribers’ accounts around the 4 of July 2024.

Advisors

Sedermera Corporate Finance AB is the Company's financial advisor in connection with the capitalization. DLA Piper has been the Company’s legal advisor.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Downloads

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.